Cystic Fibrosis Foundation
Kara Foshay, PhD is the Sr. Director of Genetic Therapy Programs at the Cystic Fibrosis Foundation. She received her PhD in Cell Biology from Georgetown University in 2008, and completed a postdoctoral fellowship with Bruce Lahn at the University of Chicago/HHMI. She was awarded NIH NRSA grants for both her doctoral and postdoctoral studies, which focused on the balance between cellular plasticity and phenotypic stability in embryonic stem cells and induced pluripotent stem cells. In 2016, she joined Inova Health Systems in Falls Church, VA where she served as Principal Investigator of the Brain Tumor Lab in the Department of Neuroscience/Neurosurgery Research. Her research utilized patient-derived glioma tissue to develop a personalized screening assay to test the potential efficacy of chemotherapy agents. Throughout her career, she has gained expertise in three-dimensional cell models, high-throughput analytics (RNAseq; ChIP-seq; LC-MS/MS) and translational assay development. Since arriving at the CFF in 2020, she has supported diverse industry-based development programs including those focused on gene delivery and gene editing technologies, lung transplant, and validation of translational models and tools. She co-leads the Preclinical Studies sub-group of the Genetic Therapies Working Group (GTWG) and lends scientific expertise to the Patient Education sub-group of the GTWG.
Friday, November 4, 2022
3:30 PM – 5:30 PM ET
Friday, November 4, 2022
3:30 PM – 5:30 PM ET